SHANGHAI, CHINA--(MARKET WIRE)--Sep 18, 2007 -- Sinobiomed Inc. (OTC BB:SOBM.OB - News) ("Sinobiomed", or "the Company") is pleased to update on clinical trial progress for the recombinant batroxobin ("rBat") made by the Company's 82% owned subsidiary, Shanghai Wanxing Bio-pharmaceuticals Co., Ltd. ("Shanghai Wanxing").
